Pharmaceuticals
Nanoscope Secures Japan MHLW Sakigake and Orphan Drug Designations Across Inherited Retinal Diseases - A First for a Retinal Gene Therapy
* Japan's Ministry of Health, Labour and Welfare (MHLW) grants MCO-010 Sakigake (Pioneering Regenerative Medical Product) and Orphan Drug designations, enabling an accelerated regulatory pathway for patients with severe inherited retinal diseases * Enhances strong global regulatory momentum, ...
2026-01-21 06:00
5575
Syngene International extends long-term research collaboration with Bristol Myers Squibb until 2035
BENGALURU, India, Jan. 21, 2026 /PRNewswire/ -- Syngene International, a global contract research, development, and manufacturing organization (CRDMO), today announced the extension of its long-standing strategic collaboration with Bristol Myers Squibb through 2035. The expanded agreement broaden...
2026-01-21 01:55
4838
Ascletis Selects a Next-Generation Once-Monthly Subcutaneously Administered GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development
- In head-to-head non-human primate (NHP) studies, average observed half-life of ASC37 was approximately 17 days, 7-fold longer than retatrutide, which supports once-monthly subcutaneous (SQ) dosing in humans. - ASC37's average in vitro activity was approximately 5-, 4-, and 4-fold more potent t...
2026-01-20 17:00
6871
Telix Achieves FY 2025 Guidance with US$804M (A$1.2B) Revenue, Accelerates Growth with Gozellix Launch
MELBOURNE, Australia and INDIANAPOLIS, Ind., Jan. 20, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") provides an update on its commercial and operational performance for the quarter ended 31 December 2025 (Q4 2025). Q4 2025 Highlights * Full-year (FY) 2...
2026-01-20 15:16
10211
AIM Vaccine's 20-Valent Pneumococcal Conjugate Vaccine Receives Clinical Approval, Upgraded Iterative Major Product Expected to Seize Domestic Opportunities
HONG KONG, Jan. 20, 2026 /PRNewswire/ -- AIM Vaccine (06660.HK), a leading domestic vaccine company, announced on January 19 that it has developed an optimized upgraded version of its iterative 20-valent pneumococcal conjugate vaccine, which has recently received clinical trial approval from the ...
2026-01-20 08:23
5325
Chinese NMPA Accepts New Drug Application for Illuccix for Prostate Cancer Imaging
MELBOURNE, Australia and INDIANAPOLIS, Jan. 20, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the Chinese National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) has accepted the filing of a New Drug Application (...
2026-01-20 06:15
5791
Sakai Clinic 62 Founder & Medical Director Mari Sakai Holds Dialogue with Peter Nobel, Chairman of the Nobel Sustainability Trust, Declaring Global Leadership as a Pioneer of Medical Sustainability
TOKYO, Jan. 20, 2026 /PRNewswire/ -- Sakai Clinic 62 (Location: Shibuya-ku, Tokyo; Founder & Medical Director: Mari Sakai) announces that Dr. Mari Sakai held a dialogue with Mr. Peter Nobel, Chairman of the Nobel Sustainability Trust (NST), to discuss the international promotion of sustainability...
2026-01-20 00:00
5816
D3 Bio Receives U.S. FDA Clearance for Two IND Applications, Enabling Phase 1 Trial of D3S‑003 and Phase 2 Combination Study of Elisrasib (D3S‑001) with D3S‑002
SHANGHAI, Jan. 19, 2026 /PRNewswire/ -- D3 Bio, a global clinical‑stage biotechnology company focused on developing transformative oncology therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has cleared two Investigational New Drug (IND) applications: * D3S‑003 — ...
2026-01-19 09:00
5544
First U.S. Patient Dosed in BiPASS: Phase 3 Prostate Cancer Diagnosis Study
MELBOURNE, Australia and INDIANAPOLIS, Jan. 16, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the first patient in the United States (U.S.) has been dosed in BiPASS™ (Biopsy of theProstate Avoidance Stratification Study), a Phase 3 trial ...
2026-01-17 03:21
4957
Antengene Presents at JPM: Strong Clinical Data Update and Strategic Focus on Next-Generation ADCs and TCEs
SHANGHAI and HONG KONG, Jan. 16, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune dis...
2026-01-16 09:00
8791
Kelun-Biotech Showcases Innovative Achievements and Future Development Strategy at the 44th Annual JPM Healthcare Conference
CHENGDU, China, Jan. 16, 2026 /PRNewswire/ -- From January 12 to 15, 2026, the 44th J.P. Morgan Healthcare Conference (JPMHC) was held in San Francisco, California, USA. Dr. Ge Michael, President and CEO of Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990....
2026-01-16 02:30
12304
/C O R R E C T I O N -- Informa Markets/
In the news release, "International Healthcare Week Returns to Thailand in 2026 with Expanded Industry Reach", issued on 15 January 2026 by Informa Markets. over PR Newswire, we are advised by the company that the testimonial featured on behalf of i-SENS, South Korea., the name mentioned should ...
2026-01-15 14:17
6842
Belief BioMed Congratulates Partner AskBio on IND Acceptance by FDA for Investigational Gene Therapy for Late-Onset Pompe Disease
SHANGHAI, Jan. 15, 2026 /PRNewswire/ -- AskBio Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, recently announced that the United States Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for AB...
2026-01-15 12:11
6380
AIM's Iterative Process High-Efficiency Diploid Rabies Vaccine Completes Phase III Clinical Trials, Efficacy Significantly Higher than Existing Market Products
HONG KONG, Jan. 15, 2026 /PRNewswire/ -- AIM Vaccine (06660.HK), a leading domestic vaccine company, announced on January 15 that its research and development of the iterative process high-efficiency diploid rabies vaccine has successfully completed the Phase III clinical site work. This marks th...
2026-01-15 08:30
7369
Lynx Analytics Introduces Lumen, an Agentic AI Framework to Improve Decision-Making in Life Sciences
LOS GATOS, Calif., Jan. 14, 2026 /PRNewswire/ -- Lynx Analytics today announced
Lumen
2026-01-14 21:00
3847
Rakuten Medical and LOTTE Biologics Sign Manufacturing Agreement to Support Biopharmaceuticals in Global Oncology Program
SEOUL, South Korea, Jan. 14, 2026 /PRNewswire/ -- Rakuten Medical, Inc. and LOTTE Biologics today announced that they have signed a biopharmaceutical contract manufacturing agreement during the J.P. Morgan Healthcare Conference in San Francisco to strengthen Rakuten Medical's production capabili...
2026-01-14 07:34
6387
Lynk Pharmaceuticals Announces Positive Phase III Topline Data of Zemprocitinib (LNK01001) in Rheumatoid Arthritis
HANGZHOU, China, SHANGHAI and BOSTON, Jan. 12, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals"), a clinical stage innovative drug development company focused on developing innovative therapies for immune and inflammatory diseases, today annou...
2026-01-12 08:00
9649
Pierre Fabre Laboratories and Iktos Announce an Integrated AI-Driven Drug Discovery Collaboration in Oncology
CASTRES, France and PARIS, Jan. 9, 2026 /PRNewswire/ -- Pierre Fabre Laboratories and Iktos, a global leader in Artificial Intelligence (AI) and Robotics on drug discovery, today announced an integrated drug discovery collaboration to identify and develop novel small-molecule drug candidates in ...
2026-01-09 15:00
10321
Ribo Life Science (06938.HK) Successfully Lists on the Main Board of the Hong Kong Stock Exchange
HONG KONG, Jan. 9, 2026 /PRNewswire/ -- Ribo Life Science Co., Ltd. ("Ribo" or the "Company", stock code: 06938.HK), a leading company in small interfering RNA (siRNA) therapeutics, today successfully listed on the Main Board of Hong Kong Stock Exchange, marking a significant milestone in the cap...
2026-01-09 13:07
15707
Telix to Present Pipeline and Commercial Portfolio Overview at J.P. Morgan Healthcare Conference
MELBOURNE, Australia and INDIANAPOLIS, Jan. 8, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today advises that Dr. Christian Behrenbruch, Managing Director and Group CEO, will be presenting at the 44th Annual J.P. Morgan Healthcare Conference being held in Sa...
2026-01-08 19:00
14300
Week's Top Stories
Most Reposted
Visa and Trip.com Group Ink Strategic Collaboration, Enabling Consumers to Chase Their Passions Through Travel
[Picked up by 309 media titles]
2026-05-19 18:10
Two-day Global Prosperity Summit 2026 officially opens
[Picked up by 308 media titles]
2026-05-19 23:59
Two‑day Global Prosperity Summit 2026 concludes successfully
[Picked up by 303 media titles]
2026-05-21 22:13
Autonomous AI marketing platform Protaigé launches with Maia, the world's first AI Account Director that operates within the flow of work
[Picked up by 281 media titles]
2026-05-20 09:15AIMX Singapore 2026 Anchors Strategic Relationship with TechInnovation and AI Gravity
[Picked up by 279 media titles]
2026-05-19 14:00
Most Read
NYSE Content Update: Lincoln International Pops by 13% in First Day of Trade
2026-05-21 21:04
7344
Scienjoy Holding Corporation Reports Unaudited First Quarter 2026 Financial Results
2026-05-21 20:30
7249
/C O R R E C T I O N -- The American Chamber of Commerce in Singapore (AmChamSG)/
2026-05-21 12:14
6490
NYSE Content Update: Armada Raises $230 Million, Boosts Valuation to $2 Billion
2026-05-19 21:02
6398
